ASX 200 falls 1.2% on Friday

The S&P/ASX 200 Index (ASX:XJO) fell by around 1.2% today. The A2 Milk Company Ltd (ASX:A2M) share price fell around 23.5%.

The S&P/ASX 200 Index (ASX: XJO) fell by around 1.2% today to 6,676 points.

Here are some of the highlights from the ASX today:

a woman

A2 Milk Company Ltd (ASX: A2M)

The A2 Milk share price fell by 23% today after the company adjusted its guidance for the FY21 first half and full year results.

A2 Milk first reminded investors that it has been saying for months it was suffering from lower sales in Australia because of daigou sales reductions with reduced tourism from China and international student numbers.

The company was previously guiding that there would be a significant increase of revenue in the second half.

However, today the company said that the disruption in the daigou channel, which represents a significant proportion of infant nutrition sales in the ANZ business, has proved to be more significant and protracted than previously anticipated. Whilst this was predominately affecting infant nutrition sales, sales in other nutritional segments have now also been impacted.

Whilst A2 Milk had expected some disruption in the FY21 second quarter, the recovery hasn't been as much as expected. It's also seeing a higher level of disruption to the cross border e-commerce channel (CBEC). The daigou channel is reportedly important for stimulating demand across multiple channels, including CBEC.

It said that the performance in the 11/11 online sales event showed year on year growth, but sales in the CBEC channel in the period after that event was below expectations.

A2 Milk is now expecting the sales for both daigou and CBEC channels for the rest of FY21 to be materially lower. The company intends to focus further on reactivating the daigou channel in the second half.

On the positive side of things, the company said its performance in Chinese 'mother and baby' stores remains very strong and it's expecting revenue growth of 40% in the first half compared to the prior corresponding period. It also said that the liquid milk businesses in Australia and the USA are performing well with growth compared to the FY20 first half.

In the first half of FY21 A2 Milk is expecting revenue of NZ$670 million, with second quarter revenue stronger than the first quarter. The earnings before interest, tax, depreciation and amortisation (EBITDA) margin for the first half is now expected to be in the order of 27%.

For the full year, the revenue is now expected to be between NZ$1.4 billion to NZ$1.55 billion. The EBITDA margin for FY21 is expected to be between 26% to 29%.  

Mesoblast Limited (ASX: MSB)

The Mesoblast share price was another to fall heavily today. It dropped by around 35% after giving an update about its trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection after the Data Safety Monitoring Board (DSMB) performed a third interim analysis on the trial's first 180 patients.

The company said that the trial was powered to achieve a primary endpoint of 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of leading care in a trial of 300 patients.

The projected mortality reduction was based on pilot data observed during the initial stages of the pandemic when control mortality rates were exceedingly high and prior to new evolving treatment regiments that have reduced disease mortality in ventilated patients.

The DSMB reported that there were no safety concerns and noted that the trial is not likely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment. The DSMB recommended that the trial complete with the currently enrolled 223 patients, and that all be followed-up as planned.

Australian Ethical Investment Limited (ASX: AEF)

The Australian Ethical share price fell 1.2% after it gave a profit update today. It said that it's expecting underlying net profit to be between $4.6 billion and $5.1 billion, which would be a mid-point increase of 11% for the six months ending 31 December 2019.

It said that funds under management (FUM) increased to $4.92 billion at 30 November 2020, up 14% from 30 September 2020 and up 21.6% since 30 June 2020.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Australian Ethical Investment Ltd. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool Australia has recommended Australian Ethical Investment Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Opinions

3 reasons why I think this leading ASX 200 share is a buy

This underrated business could be a top buy today…

Read more »

Man in shirt and tie falls face first down stairs.
Record Lows

I think this ASX 200 stock looks like a bargain after hitting an all-time low: Here's why

The ASX shares fell another 8% on Tuesday.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

Man working on a laptop from home.
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It could be another tough session for Aussie investors on hump day.

Read more »

A woman sprints with a trail of fire blazing from her body.
Opinions

I hunted the ASX for shares with the potential to double. This one stood out

Do you have this ASX share in your investment portfolio?

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »